Skip to main content
OpenTrials
Recruiting

NCT Number: NCT07340970

Sensory Stimuli During Cesarean Delivery

During a cesarean delivery (C-section), most patients are awake and receive spinal or epidural anesthesia to block pain from the lower body. Even when this anesthesia works well, many patients still feel sensations during surgery, such as pulling, pressure, tugging, or, in some cases, pain. In the past, studies have mostly focused on whether patients felt "pain," and have often relied on patients remembering their experience afterward or on the surgical team's judgment of how the patient was doing. These approaches can miss sensations that bother the patient but are not clearly described as pain, and they may not reflect what the patient actually wanted done at the time.

This study takes a different approach. Instead of asking only about pain, the researchers will ask patients, in real time during their C-section, what they are feeling in their own words, and whether they would like the medical team to do something about it (such as giving medication). The main idea is that the patient's own request for help, rather than someone else's opinion about how severe a sensation is, should be what counts as a moment that matters.

The main purpose of the study is to find out how often patients undergoing a planned C-section ask for medication in response to a sensation they feel during surgery. The researchers will ask each patient at six specific points during the operation whether they feel any sensation, how they would describe it, and whether they would like the team to act. Patients will also rate how strong each sensation is and point to where on the body they feel it. All decisions about care will remain entirely with the patient's own medical team; the research team only records what the patient reports and what care is given.

The study is also designed to answer several related questions:

* What words and descriptions do patients naturally use for the sensations they feel during a C-section? * How often are sensations that patients do not call "painful" still bothersome enough that the patient asks for medication? * How do patients' feelings and mental health change over the first six months after delivery, including symptoms of post-traumatic stress, depression, and birth-related distress? * Does a patient's anxiety before surgery affect what they feel during surgery or how likely they are to ask for help?

The main question the study is trying to answer is: How often do patients undergoing a planned cesarean delivery ask for medication because of something they feel during the operation?

The researchers' hypothesis is that this number will be higher than what earlier pain-focused studies have reported. Specifically, they expect that more than 11.5 percent of patients will ask for medication during surgery, which is greater than the rate of pain requiring extra medication found in a similar previous study. If correct, this would suggest that the true number of patients who experience moments during a C-section when they want help has been underestimated by traditional methods that focus only on pain.

This is an observational study. It does not test a new drug or change how anesthesia or surgery is performed. Instead, it carefully observes and records patients' experiences in order to better understand what patients feel during a cesarean delivery, how often they want the team to act, and how these experiences relate to their recovery and emotional well-being afterward. The goal is to use this information to improve the comfort, care, and long-term well-being of patients having a C-section.

Recruiting

Interested in participating?

Request Info

Key information

Conditions

Age range

19 year and older

Sex eligibility

Female

Study type

Observational

Primary location

BC Women's Hospital

Vancouver, British Columbia, V6H3N1, Canada

Location status: Recruiting

Location contact

Juliana Kruthof, MD, MSc, FRCPC

CONTACT

[email protected]

604-875-2158 ext. 6335

Juliana Kruthof, MD, MSc, FRCPC

PRINCIPAL_INVESTIGATOR

Katherine M Seligman, MD, FRCPC D.ABA

SUB_INVESTIGATOR

Kathryn Clark, MD, FRCPC

SUB_INVESTIGATOR

Roanne Preston, MD, FRCPC

SUB_INVESTIGATOR

Simon Massey, FRCA, FRCPC

CONTACT

[email protected]

604-875-2158 ext. 6335

Simon Massey, FRCA, FRCPC

SUB_INVESTIGATOR

William Shippam, MBChB, FRCA, FRCPC

SUB_INVESTIGATOR

About this study

Study design and setting

This is a multicenter, prospective, longitudinal observational cohort study conducted at tertiary-care obstetric centers. The coordinating center is British Columbia Women's Hospital (Vancouver, Canada), which performs approximately 15 to 20 elective cesarean deliveries under neuraxial anesthesia per week. Additional participating centers are recruited from the academic obstetric anesthesia community through the PIONEER multicenter collaborative and are added as each completes local regulatory approval and site initiation. Every center follows a common protocol with identical intraoperative assessment instruments, identical surgical timepoint definitions, identical eligibility criteria, and an identical longitudinal follow-up schedule, while preserving local institutional standards for anesthetic and surgical care. The study is conducted in compliance with the Declaration of Helsinki and the International Council for Harmonisation Good Clinical Practice guidelines.

The study is strictly observational. The research team does not participate in, direct, or influence any aspect of clinical care. All decisions about anesthesia, surgery, and the management of patient comfort rest entirely with the attending clinical team. The research team documents only what the participant reports and what care the clinical team provides.

Study procedures

Preoperative phase. Eligible patients are identified from the elective surgical schedule and approached on the day of surgery after standard preoperative nursing assessment. Following written informed consent, baseline questionnaires are completed by the participant directly in REDCap on a study device. Demographic and clinical data are collected from the participant and the medical record, including age, height, weight, body mass index, ethnicity, race, primary language, gravidity, gestational age, number of previous cesarean deliveries, surgical indication, comorbidities, psychiatric history and medication history, current medications, and baseline vital signs. Participants receive a structured orientation to the two intraoperative tools (a visual analog scale for sensation intensity and a standardized body diagram for sensation location) and practice using them in the configuration that will be used in the operating room, where the tools are positioned within the participant's field of vision and within reach of the arm bearing the pulse oximeter. Participants are told once, in a standardized manner, that any sensation they report is of interest, that there is no expected answer, and that they may decline to respond at any time.

Intraoperative phase. Anesthetic details are recorded, including neuraxial technique (single-shot spinal or combined spinal-epidural), intrathecal drugs and doses, local anesthetic agent, dose and baricity, intrathecal opioid type and dose, epidural test dose where applicable, time of neuraxial placement, dermatomal level of block to cold, pinprick, and light touch, and motor block (Bromage scale) at the start and end of surgery. For combined spinal-epidural recipients, any intraoperative epidural catheter activation is documented as a distinct event with drug, volume, and timing.

A brief standardized self-assessment is administered at six predefined surgical timepoints: (1) the surgical sharp-stimulus test performed by the surgeon immediately before skin incision, (2) skin incision, (3) uterine incision, (4) end of uterine closure (defined as completion of the final hysterotomy suture, which standardizes this timepoint across centers that do and do not perform uterine exteriorization), (5) end of fascia closure, and (6) skin closure. The timing of each assessment is recorded. At each timepoint the participant is first asked whether they feel any sensation. If they do, they are asked to describe it in their own words (recorded verbatim), to indicate whether they would like the team to do something about it, and, if so, what type of action they are requesting. Participants who report a sensation also rate its intensity on the visual analog scale and mark its location on the body diagram. Each assessment is designed to take one to two minutes.

Fetal delivery is not a standalone assessment timepoint because extraction occurs soon after uterine incision and the associated abdominal pressure precludes meaningful engagement with the assessment tools. Instead, a research team member observes and documents during the delivery interval whether the participant spontaneously reports pain or discomfort and whether the participant exhibits distress (vocalization or facial grimacing). These observer-assessed data are interpreted with appropriate caution as less reliable than self-report. Participants are also told during orientation that they may volunteer any sensation, comment, or concern at any point during surgery and need not wait for a scheduled assessment; any such spontaneous report is documented with timing relative to the nearest surgical timepoint and analyzed separately from the protocol-driven assessments.

Operative times, supplemental intravenous analgesia (by drug type and dose), anxiolytic administration before delivery, uterine exteriorization status (binary), and intraoperative events such as hemodynamic instability, nausea, vomiting, shivering, additional procedures, and estimated blood loss are recorded. At the conclusion of surgery, all participants are asked a single standardized question about whether they would have preferred general anesthesia for any part of the procedure.

Postoperative and follow-up phase. Within 24 to 48 hours after surgery and while still hospitalized, participants complete a further set of questionnaires in REDCap. In-hospital opioid consumption is recorded from end of surgery to discharge and converted to oral morphine milligram equivalents, length of stay is calculated in hours, and any postpartum complications are recorded. Longitudinal follow-up is conducted at 6 weeks, 3 months, and 6 months postpartum using secure individualized REDCap survey links, with automated invitations and telephone reminders from the local site team when questionnaires are not completed within the expected window.

Study instruments

Validated instruments are used throughout. Psychological symptoms are assessed with the PTSD Checklist for DSM-5 (PCL-5), the Edinburgh Postnatal Depression Scale (EPDS), and the Peritraumatic Distress Inventory (PDI). Preoperative anxiety is measured once with the 6-item short form of the State-Trait Anxiety Inventory (STAI-6). Sensation intensity is measured with a visual analog scale, and sensation location is recorded on a standardized body diagram coded to predefined anatomical regions. Established clinical thresholds on the psychological instruments are used to flag participants for safety follow-up.

Sample size

The sample size is determined by powering each participating center independently for the primary hypothesis test, consistent with the site-stratified meta-analytic framework. For each center, a one-sided one-sample test of a proportion was used with a null benchmark of 11.5 percent, an alternative of 17 percent, alpha of 0.05 (one-sided), and 80 percent power, yielding a minimum of 234 analyzable participants per center. To allow for an anticipated 30 percent attrition across six months of follow-up, each center targets enrollment of 335 participants. This per-site target also ensures an expected 27 to 40 events (patient-initiated requests for pharmacological intervention) per center, sufficient to support within-site multivariable adjustment for the three prespecified confounders at an events-per-variable ratio of approximately 6.75 to 10, and to provide meaningful weight in the random-effects pooling. The pooled analytical cohort scales with the number of participating centers: a minimum of two centers (at least 468 analyzable participants) is required for the multicenter analysis, with three or four centers providing progressively greater precision and enabling subgroup analyses that would be underpowered at a single site.

Statistical analysis plan

All quantitative analyses follow a site-stratified meta-analytic framework in which each center is treated as an independent analytical unit and site-specific estimates are pooled using the DerSimonian-Laird random-effects model. This approach was chosen over a single pooled regression model with site as a covariate because it preserves between-site variation as an explicit output, is better behaved with a small number of centers, and supports transparent forest-plot presentation and leave-one-center-out sensitivity analyses. Between-site heterogeneity is quantified with Cochran's Q (with p below 0.10 indicating substantive heterogeneity), the I-squared statistic (25, 50, and 75 percent interpreted as low, moderate, and substantial), and tau-squared.

The primary analysis estimates the proportion of participants who request a pharmacological intervention in response to an intraoperative sensory stimulus at one or more of the six surgical timepoints. Within each center this proportion is estimated with a 95 percent Clopper-Pearson exact confidence interval; site-specific proportions are transformed to the logit scale, pooled by the random-effects model, and back-transformed. The primary hypothesis is tested by rejecting the null (pooled incidence of 11.5 percent or less) at alpha of 0.05 when the lower bound of the one-sided 95 percent confidence interval of the pooled proportion exceeds 0.115. Site-specific one-sided exact binomial tests are reported descriptively to assess consistency of signal direction.

The primary hypothesis test is the only confirmatory analysis. All secondary analyses are exploratory and hypothesis-generating. Descriptive secondary analyses (sensory characterization, concordance between requests and supplemental analgesia, and clinical outcomes) and the qualitative thematic analysis are reported as proportions, medians, or frequencies with confidence intervals, pooled by random-effects meta-analysis where appropriate, without formal hypothesis testing. Inferential secondary analyses (associations between patient-initiated requests and exceeding clinical thresholds on the PCL-5, EPDS, and PDI, and associations between preoperative anxiety and intraoperative sensory outcomes) use within-site multivariable logistic or linear regression, with site-specific adjusted estimates pooled by random-effects meta-analysis and reported as pooled adjusted odds ratios or beta coefficients with 95 percent confidence intervals. Because the secondary analyses are exploratory, no multiplicity adjustment is applied, and results are interpreted in the context of effect size, confidence interval precision, and between-site consistency rather than reliance on p-value thresholds.

Confounder adjustment is restricted to three prespecified primary confounders to respect the events-per-variable constraint at the per-site event count: dermatomal level of sensory block (ordinal), number of previous cesarean deliveries (integer), and preoperative anxiety operationalized as the STAI-6 score (continuous). Documented psychiatric history is retained as a covariate for sensitivity analyses. Two additional prespecified variables (surgical duration and body mass index) are evaluated only in unadjusted within-site analyses and reported as hypothesis-generating. The confounder set was derived from a directed acyclic graph constructed in DAGitty to distinguish confounders from mediators (for example, supplemental analgesia administration) and colliders; the directed acyclic graph will be provided as a supplementary figure.

Longitudinal PCL-5 and EPDS trajectories are modeled within each center using generalized linear mixed-effects models with random intercepts and slopes across the five assessment timepoints; site-specific trajectory parameters are extracted and pooled by random-effects meta-analysis. The two PDI administrations (24 to 48 hours and 6 weeks) are analyzed independently as related but distinct constructs (acute versus recalled peritraumatic distress), with an exploratory within-participant change score. Qualitative responses to the open-ended sensation prompt are analyzed by inductive content analysis. Two independent investigators develop and refine a codebook through iterative open coding; inter-rater reliability is assessed on a random 20 percent subset using Cohen's kappa with a prespecified threshold of 0.70 before full coding proceeds, with a further 10 percent double-coded to confirm sustained agreement and disagreements resolved by a third investigator.

Prespecified sensitivity analyses include participant-level analyses (restriction to single-shot spinal recipients; exclusion of conversions to general anesthesia or major surgical complications; exclusion of participants with elevated baseline PCL-5 or EPDS; restriction of qualifying events to sensations rated at least 30 mm on the visual analog scale; exclusion of combined spinal-epidural participants who received epidural supplementation; and a Hawthorne-effect comparison between early and late enrollment tertiles) and site-level analyses (leave-one-center-out, a coordinating-center-only restriction, and exploratory meta-regression of site-specific incidence on site-level moderators if substantive heterogeneity is detected).

Missing data

The extent and pattern of missing data are assessed at each follow-up timepoint, overall and by center. Baseline characteristics of completers and non-completers are compared within each center and in the pooled cohort to evaluate attrition bias. The primary intraoperative analysis uses complete-case analysis because the primary outcome is captured in real time and missingness is expected to be minimal; per-site missingness rates are reported. Longitudinal models accommodate unbalanced data under a missing-at-random assumption. If missingness at any timepoint exceeds 20 percent at any center, multiple imputation by chained equations is performed at the site level as a sensitivity analysis, with re-estimated parameters pooled by random-effects meta-analysis. Because participants with adverse intraoperative experiences may be more likely to disengage from follow-up (missing not at random), a prespecified tipping-point analysis shifts imputed values toward worse outcomes in increments of 0.5 standard deviation up to 2.0 standard deviations and reports the departure from missing-at-random required to change the study's conclusions, both within each site and after pooling.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Pregnant and 19 years of age or older
  • Single (one) baby at 37 weeks of pregnancy or later
  • Overall health classified as American Society of Anesthesiologists (ASA) Physical Status II or III
  • Scheduled for a planned (elective) cesarean delivery using spinal anesthesia (single-shot spinal or combined spinal-epidural)
  • Able to describe sensations in their own words in one of the study's available languages
  • Willing and able to give written informed consent before any study procedures
  • Willing and able to complete online follow-up questionnaires at 6 weeks, 3 months, and 6 months after delivery

Exclusion criteria

  • History of a chronic pain condition (for example, fibromyalgia, chronic pelvic pain, complex regional pain syndrome, or chronic low back pain requiring ongoing treatment)
  • Regular use of opioids, gabapentinoids (gabapentin or pregabalin), or other centrally acting pain medications during the current pregnancy (occasional acetaminophen use is allowed)
  • History of a neurological condition that can affect normal sensation (for example, peripheral neuropathy, multiple sclerosis, or spinal cord injury)
  • Pregnancy with more than one baby (twins or more)
  • Cesarean delivery planned with an anesthesia method other than single-shot spinal or combined spinal-epidural (for example, topping up an existing labor epidural, or general anesthesia)
  • Known major fetal abnormality or an expected newborn complication likely to require immediate admission to the neonatal intensive care unit (NICU)
  • Known allergy or other reason the local anesthetic medications used for spinal anesthesia cannot be given
  • Active substance use disorder

Treatment and study plan

Patient-initiated request for pharmacological intervention during cesarean delivery

Other

The exposure of interest is the participant's own request, made during cesarean delivery, for the clinical team to provide a pharmacological intervention in response to an intraoperative sensory stimulus. At each of six predefined surgical timepoints, participants who report a sensation are asked whether they would like the team to act and, if so, whether they are requesting medication, some other action, or both. A request that includes medication constitutes the exposure. This is an observed, patient-initiated event; investigators do not assign or administer it, and all clinical management remains at the discretion of the treating team. This exposure is linked to the single study cohort (Elective cesarean delivery under neuraxial anesthesia).

Primary outcomes

  1. Proportion of participants who request a Pharmacological Intervention in Response to an Intraoperative Sensory Stimulus

    Time frame: Intraoperative; assessed across the six surgical timepoints from the surgical sharp-stimulus test (immediately before skin incision) through skin closure during the cesarean delivery (typically up to approximately 90 minutes)

    At each of six predefined surgical timepoints (surgical sharp-stimulus test before skin incision, skin incision, uterine incision, end of uterine closure, end of fascia closure, and skin closure), participants who report a sensation are asked: "Is there anything you would like us to do to address the sensation, like giving you medication or some other action?" A participant meets the outcome if, at one or more timepoints, the request includes medication (alone or together with some other action). Requests for some other action only, and timepoints with no affirmative response, are counted as non-events. The measure is the proportion (percentage) of participants with at least one qualifying request: the numerator is participants requesting a pharmacological intervention; the denominator is all analyzable participants. Site-specific proportions are pooled across participating centers using a DerSimonian-Laird random-effects model.

Secondary outcomes

  1. Thematic Categories of Patient-Reported Descriptions of Intraoperative Sensory Experiences

    Time frame: Intraoperative; verbatim descriptions collected across the six surgical timepoints from the surgical sharp-stimulus test through skin closure during the cesarean delivery (up to approximately 90 mins)

    Verbatim responses to the standardized open-ended prompt "How would you describe the sensation you are feeling?", administered at each of six predefined surgical timepoints to participants who report a sensation, are analyzed by inductive qualitative content analysis. Sensory categories are derived inductively from participants' own descriptions rather than predefined classifications. Two independent investigators develop and refine a codebook through iterative open coding; inter-rater reliability is assessed on a random subset using Cohen's kappa (prespecified threshold 0.70) before full coding. The outcome is the set of thematic categories of intraoperative sensory experience, reported with the frequency of each category and its distribution across the six surgical timepoints. Reported per the Standards for Reporting Qualitative Research (SRQR).

  2. Incidence of Each Type of Patient-Reported Sensory Experience at Each Surgical Timepoint

    Time frame: Intraoperative; assessed at each of the six surgical timepoints from the surgical sharp-stimulus test through skin closure during the cesarean delivery (up to approximately 90 mins)

    At each of six predefined surgical timepoints (surgical sharp-stimulus test before skin incision, skin incision, uterine incision, end of uterine closure, end of fascia closure, and skin closure), participants report whether they feel any sensation. Sensory categories are derived inductively from participants' own verbatim descriptions rather than predefined classifications (see the qualitative content analysis). For each surgical timepoint, the incidence of any reported sensation and of each inductively derived sensory category is calculated as the proportion (percentage) of participants reporting that sensation. Site-specific proportions are estimated with 95% Clopper-Pearson exact confidence intervals and pooled across participating centers using a DerSimonian-Laird random-effects model on the logit scale, with back-transformation to the proportion scale.

  3. Intensity of Patient-Reported Intraoperative Sensation Measured on a 100-mm Visual Analog Scale at Each Surgical Timepoint

    Time frame: Intraoperative; assessed at each of the six surgical timepoints from the surgical sharp-stimulus test through skin closure during the cesarean delivery (up to approximately 90 mins)

    Participants who report a sensation at a given surgical timepoint rate its intensity on a 100-mm horizontal Visual Analog Scale (VAS), anchored at the left end by "no sensation" (0 mm) and at the right end by "worst imaginable sensation" (100 mm); higher scores indicate greater intensity. The score is the distance in millimeters from the left anchor to the participant's mark (continuous, range 0 to 100 mm). Intensity is assessed at each of six predefined surgical timepoints (surgical sharp-stimulus test before skin incision, skin incision, uterine incision, end of uterine closure, end of fascia closure, and skin closure). For each timepoint, VAS scores are summarized within each participating center as medians with interquartile ranges and pooled across centers by random-effects meta-analysis.

  4. Anatomical Distribution of Patient-Reported Intraoperative Sensations Recorded on a Standardized Body Diagram at Each Surgical Timepoint

    Time frame: Intraoperative; assessed at each of the six surgical timepoints from the surgical sharp-stimulus test through skin closure during the cesarean delivery (up to approximately 90 mins)

    Participants who report a sensation at a given surgical timepoint indicate its location on a standardized body diagram. Each marked location is coded to a set of predefined anatomical regions specified a priori in the body-diagram coding key. At each of six predefined surgical timepoints (surgical sharp-stimulus test before skin incision, skin incision, uterine incision, end of uterine closure, end of fascia closure, and skin closure), the outcome is the proportion (percentage) of participants reporting sensation in each anatomical region. Site-specific proportions are pooled across participating centers using a DerSimonian-Laird random-effects model on the logit scale, with back-transformation to the proportion scale. Distributions are additionally cross-tabulated by sensory category and by surgical timepoint to describe spatial and spatiotemporal patterns.

  5. Temporal Pattern of Patient-Reported Intraoperative Sensations Across the Six Surgical Timepoints

    Time frame: Intraoperative; assessed across the six surgical timepoints from the surgical sharp-stimulus test through skin closure during the cesarean delivery (up to approximately 90 mins)

    Using the timepoint-specific sensory data, the distribution of reported sensations is examined across the six predefined surgical timepoints (surgical sharp-stimulus test before skin incision, skin incision, uterine incision, end of uterine closure, end of fascia closure, and skin closure) to characterize how the incidence and intensity of sensation change over the course of surgery. The outcome identifies the surgical timepoint(s) associated with the highest incidence of patient-initiated requests for pharmacological intervention and the highest median Visual Analog Scale intensity among reported sensations. Patterns are determined within each participating center and at the pooled level (DerSimonian-Laird random-effects model) to evaluate consistency of the temporal pattern across centers.

  6. Proportion of Non-Pain Sensory Stimuli That Prompted a Patient Request for Pharmacological Intervention

    Time frame: Intraoperative; sensory events and associated requests collected across the six surgical timepoints from the surgical sharp-stimulus test through skin closure during the cesarean delivery (up to approximately 90 mins)

    This event-level outcome quantifies the extent to which sensations not explicitly described as painful nonetheless prompted a patient-initiated request for pharmacological intervention. Each reported sensory event (across all six surgical timepoints) is classified by the participant's own verbatim description as pain or non-pain (e.g., pressure, pulling, visceral sensation) using the inductively derived sensory categories. Among events not described as painful, the outcome is the proportion (percentage) that prompted a request for pharmacological intervention, analyzed by sensory category and by surgical timepoint. Unlike the patient-level primary outcome, this measure operates at the level of individual sensory events. Site-specific proportions are pooled across participating centers using a DerSimonian-Laird random-effects model.

  7. Concordance Between Patient-Initiated Requests for Pharmacological Intervention and Receipt of Supplemental Intraoperative Analgesia

    Time frame: Intraoperative; requests and analgesia administration recorded across the six surgical timepoints from the surgical sharp-stimulus test through skin closure during the cesarean delivery (up to approximately 90 mins)

    For each participant, patient-initiated requests for pharmacological intervention are compared with the supplemental intraoperative analgesia actually administered by the clinical team (recorded by drug, dose, and route). The outcome comprises three measures, each reported as a proportion (percentage): the overall concordance rate (agreement between request and subsequent administration); the rate of unmet requests (a request not followed by administration of analgesia); and the rate of unsolicited analgesia administration (analgesia given without a preceding patient request). All clinical management decisions rest with the treating clinician; the research team records only the request and the intervention provided. Site-specific rates are pooled across participating centers using a DerSimonian-Laird random-effects model.

  8. PTSD Checklist for DSM-5 (PCL-5) Total Score at Each Assessment Timepoint

    Time frame: Preoperative baseline (day of surgery), 24 to 48 hours postpartum, and 6 weeks, 3 months, and 6 months postpartum (up to a maximum of 183 days)

    The PTSD Checklist for DSM-5 (PCL-5) is a 20-item self-report measure of post-traumatic stress symptoms. Each item is rated 0 ("not at all") to 4 ("extremely"), yielding a total score from 0 to 80; higher scores indicate greater symptom severity. At baseline, participants rate symptoms over the past month; at postpartum timepoints they reference the cesarean delivery as the index event. The total score is reported at each of five assessment timepoints: preoperative baseline, 24 to 48 hours postpartum, 6 weeks, 3 months, and 6 months postpartum. Scores are summarized within each participating center, and longitudinal trajectories are modeled using mixed-effects models with site-specific parameters pooled across centers by a DerSimonian-Laird random-effects model.

  9. Edinburgh Postnatal Depression Scale (EPDS) Total Score at Each Assessment Timepoint

    Time frame: Preoperative baseline (day of surgery), 24 to 48 hours postpartum, and 6 weeks, 3 months, and 6 months postpartum (up to a maximum of 183 days)

    The Edinburgh Postnatal Depression Scale (EPDS) is a 10-item self-report measure that screens for depressive symptoms in the perinatal period. Each item is scored 0 to 3, yielding a total score from 0 to 30; higher scores indicate greater depressive symptom severity. The total score is reported at each of five assessment timepoints: preoperative baseline, 24 to 48 hours postpartum, 6 weeks, 3 months, and 6 months postpartum. Scores are summarized within each participating center, and longitudinal trajectories are modeled using mixed-effects models with site-specific parameters pooled across centers by a DerSimonian-Laird random-effects model.

  10. Peritraumatic Distress Inventory (PDI) Total Score at 24 to 48 Hours and 6 Weeks Postpartum

    Time frame: 24 to 48 hours postpartum and 6 weeks postpartum (up to a maximum of 42 days)

    The Peritraumatic Distress Inventory (PDI) is a 13-item self-report measure of emotional distress experienced during and immediately after a traumatic event. Each item is rated 0 ("not at all true") to 4 ("extremely true"), yielding a total score from 0 to 52; higher scores indicate greater peritraumatic distress. The total score is reported at two assessment timepoints: 24 to 48 hours postpartum (acute peritraumatic distress, the primary peritraumatic measure) and 6 weeks postpartum (recalled peritraumatic distress). The two administrations are analyzed independently as related but distinct constructs. Scores are summarized within each participating center and pooled across centers by a DerSimonian-Laird random-effects model. The PDI is not administered at baseline, as peritraumatic distress by definition relates to a specific event.

  11. Proportion of Participants Exceeding Validated Clinical Thresholds on the PCL-5, EPDS, and PDI at Each Postpartum Assessment Timepoint

    Time frame: PCL-5 and EPDS: 24 to 48 hours, 6 weeks, 3 months, and 6 months postpartum. (up to a maximum of 183 days) PDI: 24 to 48 hours and 6 weeks postpartum (up to a maximum of 42 days).

    At each postpartum assessment timepoint, the outcome is the proportion (percentage) of participants whose scores exceed validated clinical thresholds on each instrument: PCL-5 of 31 or higher (probable PTSD; scale 0 to 80), EPDS above 10 (depression risk; scale 0 to 30), and PDI of 15 or higher (significant peritraumatic distress; scale 0 to 52). On all three instruments, higher scores indicate greater symptom severity. PCL-5 and EPDS thresholds are assessed at 24 to 48 hours, 6 weeks, 3 months, and 6 months postpartum; the PDI threshold is assessed at 24 to 48 hours and 6 weeks postpartum. Site-specific proportions are pooled across participating centers using a DerSimonian-Laird random-effects model.

  12. Association Between Patient-Initiated Requests for Pharmacological Intervention and Exceeding Clinical Thresholds on the PCL-5, EPDS, and PDI

    Time frame: Psychological thresholds assessed at 24 to 48 hours, 6 weeks, 3 months, and 6 months postpartum (PDI at 24 to 48 hours and 6 weeks only), in relation to the intraoperative primary outcome (up to a maximum of 183 days)

    This outcome evaluates whether participants who made a patient-initiated request for pharmacological intervention during surgery (the binary primary outcome) are more likely to exceed validated clinical thresholds on the psychological instruments postpartum: PCL-5 of 31 or higher, EPDS above 10, and PDI of 15 or higher. Within each participating center, the association is estimated using multivariable logistic regression adjusted for three prespecified confounders (dermatomal level of sensory block, number of previous cesarean deliveries, and preoperative STAI-6 score). Site-specific adjusted odds ratios are pooled across centers using a DerSimonian-Laird random-effects model and reported as pooled adjusted odds ratios with 95% confidence intervals at each postpartum timepoint. This analysis is exploratory and hypothesis-generating.

  13. Preoperative Anxiety (STAI-6) and Its Association With Intraoperative Sensory Outcomes and Patient-Initiated Treatment Requests

    Time frame: STAI-6 measured at preoperative baseline (day of surgery); intraoperative sensory outcomes assessed across the six surgical timepoints during the cesarean delivery (up to a maximum of 1 day)

    Preoperative anxiety is measured once at baseline using the 6-item State-Trait Anxiety Inventory short form (STAI-6). Each item is rated 1 to 4; the raw total (6 to 24) is multiplied by 20/6 to give a transformed score on the standard 20 to 80 scale, where higher scores indicate greater anxiety and a transformed score of 40 or higher denotes clinically significant anxiety. Reported as the mean transformed score and the proportion of participants exceeding the cutoff. The association between STAI-6 score and intraoperative sensory outcomes (the binary primary outcome, VAS intensity, and timepoint-specific incidence of sensation) is estimated within each participating center by multivariable regression adjusted for dermatomal level and number of previous cesarean deliveries, with site-specific estimates pooled by a DerSimonian-Laird random-effects model (adjusted odds ratios or beta coefficients, 95% CI).

  14. Proportion of Participants Who Indicated They Would Have Preferred General Anesthesia for Any Part of the Surgery

    Time frame: Assessed once at the conclusion of surgery (end of the cesarean delivery) (up to a maximum 90 mins)

    At the conclusion of surgery, all participants (regardless of whether they requested any intraoperative intervention) are asked a single standardized yes/no question: "Overall, would you have preferred to receive general anesthesia (i.e., be asleep) for any part of this surgery?" The outcome is the proportion (percentage) of participants answering yes. This captures the full spectrum of intraoperative experience, including participants who found their experience distressing without requesting treatment during surgery. Site-specific proportions are estimated with 95% Clopper-Pearson exact confidence intervals and pooled across participating centers using a DerSimonian-Laird random-effects model.

  15. Total Supplemental Intraoperative Intravenous Analgesia Administered, by Drug Type and Cumulative Dose

    Time frame: Intraoperative; from neuraxial placement through the end of the cesarean delivery (up to a maximum of 90 mins)

    The total supplemental intravenous analgesia administered by the clinical team during surgery is recorded by drug type and cumulative dose (including agents such as fentanyl, ketamine, and dexmedetomidine). The outcome reports, for each drug, the proportion of participants who received it and the cumulative dose administered (summarized as median with interquartile range or mean with standard deviation, as appropriate to the distribution). All administration decisions rest with the treating clinician; the research team records only what was given. Site-specific summaries are pooled across participating centers using a DerSimonian-Laird random-effects model.

  16. In-Hospital Opioid Consumption From End of Surgery to Discharge, in Oral Morphine Milligram Equivalents (MME)

    Time frame: From end of surgery to hospital discharge (up to a maximum of 7 days)

    Total opioid consumption from the end of surgery to hospital discharge is recorded (including agents such as fentanyl, hydromorphone, and morphine) and converted to a common unit of oral morphine milligram equivalents (MME). The outcome is the cumulative MME per participant, summarized within each participating center as median with interquartile range or mean with standard deviation, as appropriate to the distribution, and pooled across participating centers using a DerSimonian-Laird random-effects model.

  17. Length of Hospital Stay From End of Surgery to Discharge

    Time frame: From end of surgery to official hospital discharge (up to a maximum of 7 days)

    Length of hospital stay is defined as the total duration, in hours, from the end of surgery to official hospital discharge. The outcome is summarized within each participating center as median with interquartile range or mean with standard deviation, as appropriate to the distribution, and pooled across participating centers using a DerSimonian-Laird random-effects model.

Study contacts

Contact information is provided by the study sponsor or research team.

Juliana Kruthof, MD, MSc, FRCPC

CONTACT

[email protected]

604-875-2424 ext. 6335

Sponsors and collaborators

Lead sponsor

University of British Columbia

Other

Collaborators

  • University of Arkansas
  • Western University, Canada

Registry information

Official study title

Patient Perception of Sensory Stimuli During Elective Cesarean Delivery Under Neuraxial Anesthesia (PIONEER): A Multicenter Prospective Cohort Study

Acronym: PIONEER-MC

Important dates

Study start
2026
Primary completion
2027
Study completion
2027
First posted
Jan 14, 2026
Registry last updated
Aug 3, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.